Alector LLC

Genentech, Inc.

Rinat Neuroscience Corporation

Labrys Biologics, Inc.

Annexon, Inc.

Teva Pharmaceuticals International Gmbh

Pfizer Corporation

Genetech, Inc.

University of California

Arnon Rosenthal

Jaume Pons

Tina Schwabe

Seung-Joo Lee

Yasmina Noubia Abdiche

Kristian Todd Poulsen

Joerg Zeller

Sierra Jones Collier

Helen Lam

Frederic J De Sauvage

Wei-Hsien Ho

Patricia Culp

Robert Pejchal

Robert D Klein

Michael Kurnellas

Kate Monroe

Michael W Leviten

Andrew Pincetic

Herve Rhinn

Anthony B Cooper

David L Shelton

Mark W Moore

Austin L Gurney

William I Wood

Jeonghoon Sun

Alan S Verkman

Ilaria Tassi

Francesca Avogadri-Connors

Angie Grace Yee

Donna Marie Stone

Philip Ling Kong

Maximilien Murone

Patricia Ann Walicke

Mary A Hynes

Nels P Nielson

Muhammad Abbas Alhawagri

Jan Markus Grimm

Eric Brown

Anne M Ryan

William Monteith

Heidi S Phillips

Ted A Yednock

Sethu Sankaranarayanan

John William Winslow

Spencer Liang

Marina Roell

Weilan Ye

Asa Abeliovich

Stephen Charles Phillips

Leonard Presta

Hua Long

Ananya Mitra

Sierra Leigh Jones Collier

Rashmi Bankoti

Klaus-Dieter Heger

Francesca Cignarella

Daniel P Bermingham

Santiago Viveros Salazar

Karpagam Srinivasan

Frederick J De Sauvage

Ian William Mills

David Peter Scholfield

Sierra Lee Jones Collier

John (Chia-Yang) Lin

John Chia-Yang Lin

Francesca Avogadri-connors

David Louis Shelton

Robert Pejchat

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-Sortilin antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A4A antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-TMEM106B antibodies and methods of use thereof

Anti-sortilin antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-SIRPα antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-Siglec-5 antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-CD33 antibodies and methods of use thereof

The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.

Anti-SIRP-alpha antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-Siglec-7 antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A6A antibodies and methods of use thereof

The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.

Methods of screening for sortilin binding antagonists

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-TREM1 antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPβ1 polypeptide, e.g., a human SIRPβ1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-SIRP-Beta1 antibodies and methods of use thereof

Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.

Siglec transgenic mice and methods of use thereof

Growing community of inventors

Woodside, CA, United States of America

Arnon Rosenthal